Table 2.
Markers of inflammation and immunosuppression at baseline.
| Variables at trial inclusion | Total (n = 20) | Clazakizumab (n = 10) | Placebo (n = 10) |
|---|---|---|---|
| Markers of inflammation | |||
| CRP (mg/dl), median (IQR) | 0.20 (0.05–0.44) | 0.13 (0.04–0.26) | 0.42 (0.08–0.48) |
| IL‐6 (pg/ml), median (IQR) | 1.53 (0.83–2.44) | 1.38 (0.79–2.34) | 1.60 (0.83–2.58) |
| Maintenance immunosuppression | |||
| Triple immunosuppression | 18 (90) | 9 (90) | 9 (90) |
| Dual immunosuppression without steroids | 2 (10) | 1 (10) | 1 (10) |
| Immunosuppressants | |||
| Tacrolimus, n (%) | 13 (65) | 6 (60) | 7(70) |
| C0 level (ng/ml), median (IQR) | 6.0 (5.2–7.1) | 5.6 (4.3–7.4) | 6.0 (5.6–7.0) |
| CyA, n (%) | 6 (30) | 4 (40) | 2 (20) |
| C0 level (ng/ml), median (IQR) | 123 (103–152) | 138 (115–170) | 85, 114 |
| Everolimus, n (%) | 1 (5) | 0 | 1 (10) |
| C0 level (mg/ml) | 5.4 | ‐ | 5.4 |
| MMF, n (%) | 10 (50) | 6 (60) | 4 (40) |
| EC‐MPA, n (%) | 10 (50) | 4 (40) | 6 (60) |
| Steroid, n (%) | 18 (90) | 9 (90) | 9 (90) |
CRP, C‐reactive protein; CyA, cyclosporin A; EC‐MPA, enteric‐coated mycophenolic acid; IL‐6, interleukin‐6; IQR, interquartile range; MMF, mycophenolate mofetil.